Pediatric HIV/AIDS Cohort Study (PHACS -BCH site only)

  • Principal Investigator(s): Sandra Burchett (site leader), George Seage PI
  • Study Contact: Sandra Burchett, MD, Tel. 617 355-6832, sandra.burchett@childrens.harvard.edu
  • Description of Subjects: AMP:450 HIV+ youth, 150 HIV-controls; SMARRT: >1700 HIV neg/ARV exposed infants,youth. Study domains: cardiopulm, metabol, complications and HIV disease, maternal exposures, neuro, oral health, adolescent
  • Location (Domestic vs. International): Domestic, Boston Children's in MA but multicenter (George Seage, PI, HSPH)
  • Enrollment Period: 2007-present
  • Enrollment Goal: AMP:450 HIV+ youth, 150 HIV-controls; SMARRT: >1700 HIV neg/ARV exposed infants,youth.
  • Key Exclusion and Inclusion Criteria: AMP: perinatal infection enroll between ages of 7-16, follow long term, database from birth. SMARRT: mother with HIV, infants exposed to ARV, uninfected, database from birth follow to 25
  • Available Biological Specimens and Data: Yes, B-cell lines, Blood, serum, plasma, and DNA. Data from our Surveillance Monitoring for ART Toxicities (SMARTT) and Adolescent Master Protocol (AMP) studies are now available through NICHD DASH
  • How to Request Access: Please contact Dr. Burchett with initial idea so she can appropriately link you with the proper working group.
  • Mechanism for Requesting Samples: Database collaborations are welcome, and specimens may be shared. Multicenter, NICHD funded, AMP (HIV+/-youth); SMARRT(HIV-, ARV exposed babies.
  • Available Data Description: CD4, VL, longitudinal data, co-infections, vaccines, neurodevelop testing, adherence, ARVs, acasi, oral health in HIV+, pulmonary ftn testing, echos, dexas, lab data
See also: B-Cell Lines, Blood, serum, and plasma, DNA, HIV+ and HIV-, Boston Children's Hospital, Studies > 1000 Participants, Studies Started Post-2005, Domestic, George R Seage, III, Sandra Burchett, Multi-site Networks, Pediatrics